Emerging as a promising breakthrough in the struggle against obesity, the drug is attracting considerable attention . This treatment combines the action of two established GLP-1 receptor agonists, semaglutide , plus an new glucose-dependent incretin component. Preliminary clinical findings have indicated substantial fat decrease in individuals w… Read More